Entera Bio's EBIT per Share for the
three
months ended in Dec. 2023 was $-0.07.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.31.
During the past 3 years, the average EBIT per Share Growth Rate was 20.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 24.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Entera Bio's EBIT per Share or its related term are showing as below:
ENTX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -63.6 Med: 17.15 Max: 30
Current: 20.3
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Entera Bio was 30.00% per year. The lowest was -63.60% per year. And the median was 17.15% per year.
ENTX's 3-Year EBIT Growth Rate is ranked better than 71.34% of 1305
companies
in the Biotechnology industry
Industry Median: 3.5
vs ENTX: 20.30
Entera Bio's EBIT for the
three
months ended in Dec. 2023 was $-1.96 Mil.
Entera Bio EBIT per Share Historical Data
The historical data trend for Entera Bio's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entera Bio (NAS:ENTX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Entera Bio EBIT per Share Related Terms
Thank you for viewing the detailed overview of Entera Bio's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENTX has been successfully added to your 